Nikon Instruments Inc. (Nikon) is pleased to announce the establishment of the Nikon BioImaging Lab Lexington in Massachusetts, USA, where it will provide ...
Celltrion USA announced the submission of Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for CT-P47, a biosimilar...
QIAGEN announced a first-in-kind collaboration with Penn State University in the United States to create a shared research and education facility for the f...
Biocytogen’s fully human antibody sequences were generated by proprietary RenMice strains, each engineered to lack a certain drug target gene. From M...
Maureen Deehan, CEO of Vivtex, commented: “We are delighted to enter this new collaboration with Astellas Pharma. Over the past few years, Vivtex has...
ProteinLogic extends ImmiPrint® Technology to address TB antimicrobial chemotherapy response monitoring. ProteinLogic ImmiPrint® diagnostic patt...
In a significant move, Agappe and Fujirebio have revealed plans to launch these products in June 2024. The project has already achieved significant progres...
The acquisition is expected to close on February 1, 2024, subject to customary closing conditions. By bringing the Precise Tumor and Precise Liquid tests i...
Novel class of antibiotics Bactericidal activity demonstrated in vitro and in vivo against broad range of Gram-negative bacteria, including multidrug-re...
Sequentify, a company specializing in DNA sequencing technology, has been granted funding by the Israel Innovation Authority (IIA). This grant, contr...
-DNAnexus, Inc., the provider of the Precision Health Data Cloud, and Intelliseq, a genome informatics company and innovative provider of next-generation s...
-Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that the Saudi Food and Drug Authority (SFDA) granted Marketing Authorization for CASGE...
The company is set to introduce multi-omics capabilities on the AVITI platform, along with enhancements to the first commercial Q50 kit and a host of workf...
- Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein met the primary immunogenicity endpoint, eliciting a robust imm...
© 2024 Biopharma Boardroom. All Rights Reserved.